Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial
The purpose of this study is to determine if Gadofosveset Trisodium (Gdfos, Ablavar) is a
useful magnetic resonance imaging (MRI) contrast agent in accurately diagnosing liver
metastases compared to the standard agent gadobutrol (EcGd, Gadovist).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society